Imaxio Attains CSP Status for Agilent's SureSelect System for NGS | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies said today that French biotech firm Imaxio has achieved Certified Service Provider status for the SureSelect Target Enrichment System for next-generation sequencing.

Imaxio was already a CSP for Agilent's microarray services and participated in comprehensive on-site training and passed a set of requirements demonstrating expertise and skill to receive CSP status for the SureSelect system, Agilent said. SureSelect is compatible with major NGS platforms, such as Illumina, Life Technologies' SOLiD, and Roche's 454.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.